Crowley John J Insider Trades

Insider Trading History

Track insider trading activity for Crowley John J. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc CNTA
Chief Financial Officer
Holding Value $7.21M 181,000 shares
Last Trade
Feb 02, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$5.69M 226,000 shares
$25.19
$39.85
Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc CNTA
Chief Financial Officer
Holding Value $9.96M 250,000 shares
Last Trade
Feb 03, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$4.23M 250,000 shares
$16.90
$39.85
Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc CNTA
Chief Financial Officer
Holding Value $23.9M 600,000 shares
Last Trade
Jul 01, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$5.28M 600,000 shares
$8.80
$39.85
Fusion Pharmaceuticals
Fusion Pharmaceuticals FUSN
Chief Financial Officer
Holding Value $0 0 shares
Last Trade
Jun 04, 2024 Sale (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$24.7M 1,147,982 shares
$21.55
$21.55
Fusion Pharmaceuticals
Fusion Pharmaceuticals FUSN
Chief Financial Officer
Holding Value $2.29M 106,100 shares
Last Trade
Jan 04, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$895k 106,100 shares
$8.44
$21.55
Fusion Pharmaceuticals
Fusion Pharmaceuticals FUSN
Chief Financial Officer
Holding Value $5.39M 250,000 shares
Last Trade
Jan 05, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$938k 250,000 shares
$3.75
$21.55
Fusion Pharmaceuticals
Fusion Pharmaceuticals FUSN
Chief Financial Officer
Holding Value $3.6M 167,000 shares
Last Trade
Feb 01, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.29M 167,000 shares
$7.70
$21.55
Fusion Pharmaceuticals
Fusion Pharmaceuticals FUSN
Chief Financial Officer
Holding Value $224k 10,410 shares
Last Trade
Aug 31, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$36.5k 3,910 shares
$9.33
$21.55
Fusion Pharmaceuticals
Fusion Pharmaceuticals FUSN
Chief Financial Officer
Holding Value $2.97M 138,000 shares
Last Trade
Feb 04, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.64M 138,000 shares
$11.90
$21.55
Fusion Pharmaceuticals
Fusion Pharmaceuticals FUSN
Chief Financial Officer
Holding Value $140k 6,500 shares
Last Trade
Jun 30, 2020 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$111k 6,500 shares
$17.00
$21.55
Fusion Pharmaceuticals
Fusion Pharmaceuticals FUSN
Chief Financial Officer
Holding Value $1.31M 60,852 shares
Last Trade
Jun 25, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$21.55
Fusion Pharmaceuticals
Fusion Pharmaceuticals FUSN
Chief Financial Officer
Holding Value $0 0 shares
Last Trade
Jun 25, 2020 Sale
No data
No data
$21.55
Fusion Pharmaceuticals
Fusion Pharmaceuticals FUSN
Chief Financial Officer
Holding Value $831k 38,561 shares
Last Trade
Feb 06, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$21.55
Charles River Laboratories International
Charles River Laboratories International CRL
Svp, Chief Accounting Officer
Holding Value $1.01M 5,599 shares
Last Trade
Oct 01, 2016 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$23.7k 284 shares
$83.34
$179.87
Charles River Laboratories International
Charles River Laboratories International CRL
Svp, Chief Accounting Officer
Holding Value $1.06M 5,883 shares
Last Trade
May 24, 2016 Sale (Open Market)Shares sold on the open market or in a private sale.
$163k 1,913 shares
$85.00
$179.87
Charles River Laboratories International
Charles River Laboratories International CRL
Svp, Chief Accounting Officer
Holding Value $1.4M 7,796 shares
Last Trade
May 24, 2016 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$163k 1,913 shares
$85.41
$179.87
Charles River Laboratories International
Charles River Laboratories International CRL
Svp, Chief Accounting Officer
Holding Value $360k 2,000 shares
Last Trade
May 24, 2016 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$163k 1,913 shares
$85.41
$179.87
Charles River Laboratories International
Charles River Laboratories International CRL
Svp, Chief Accounting Officer
Holding Value $1.06M 5,883 shares
Last Trade
Feb 28, 2016 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$5.6k 76 shares
$73.70
$179.87
Charles River Laboratories International
Charles River Laboratories International CRL
Svp, Chief Accounting Officer
Holding Value $1.07M 5,959 shares
Last Trade
Feb 27, 2016 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$5.01k 68 shares
$73.70
$179.87
Charles River Laboratories International
Charles River Laboratories International CRL
Svp, Chief Accounting Officer
Holding Value $1.08M 6,027 shares
Last Trade
Feb 26, 2016 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$476k 6,453 shares
$73.70
$179.87

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up